Effect Of Tezepelumab On Rescue Medication Use And Night-Time Awakenings In Patients With Severe, Uncontrolled Asthma: Results From The NAVIGATOR Study - 03/02/23
Doi : 10.1016/j.jaci.2022.12.052
Warner Carr, MD, FAAAAI 1, Chris Ambrose, MD, MBA 2, Gillian Hunter, MSc 3, Sandhia Ponnarambil 4, Jean-Pierre Llanos-Ackert 5, Nicole Clarke 6, Bill Cook, PhD 2
1 Allergy & Asthma Associates of Southern California, Mission Viejo, CA, USA
2 Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA
3 Biometrics, Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
4 Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
5 Global Medical Affairs, Amgen, Thousand Oaks, CA, USA
6 Patient-centered Science, Respiratory and Immunology, AstraZeneca, Gaithersburg, MD, USA
046
Il testo completo di questo articolo è disponibile in PDF.Mappa
© 2022
Pubblicato da Elsevier Masson SAS.
Vol 151 - N° 2S
P. AB14 - Febbraio 2023 Ritorno al numero
Articolo precedente
- Withdrawn
- Long-Term Dupilumab Treatment Effect On Safety And Clinical Efficacy In Children With Type 2 Asthma: LIBERTY ASTHMA EXCURSION
- Leonard Bacharier, Jorge Maspero, Constance Katelaris, Alessandro Fiocchi, Remi Gagnon, Ines de Mir, Theresa Guilbert, Daniel Jackson, Ning Li, Bolanle Akinlade, Elizabeth Laws, Leda Mannent, Jennifer Maloney, Kelsey Tawo, Faisal Khokhar, Megan Hardin, Raolat Abdulai, David Lederer, Lacey Robinson
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?